TNGX
Company Description
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 62.38M | 42.07M | 36.53M | 24.86M | 37.04M | 7.66M | 24.65M |
| Net Income | (101.59M) | (130.30M) | (101.74M) | (108.18M) | (58.23M) | (51.97M) | (14.10M) |
| EPS | -0.87 | -1.19 | -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| Free Cash Flow | (139.93M) | (132.25M) | (119.51M) | (116.77M) | (61.36M) | 68.97M | (26.62M) |
| FCF / Share | -1.20 | -1.21 | -1.26 | -1.33 | -0.99 | 0.79 | -0.30 |
| Operating CF | (138.89M) | (131.50M) | (117.98M) | (109.08M) | (59.53M) | 70.07M | (24.80M) |
| Total Assets | 398.69M | 316.49M | 402.57M | 436.47M | 500.15M | 207.25M | 55.76M |
| Total Debt | 33.57M | 36.49M | 38.92M | 41.13M | 1.50M | 7.88M | 8.54M |
| Cash & Equiv | 112.28M | 69.53M | 66.39M | 59.97M | 142.75M | 28.38M | 22.89M |
| Book Value | 346.18M | 199.52M | 253.11M | 249.48M | 344.75M | 38.60M | 7.91M |
| Return on Equity | -0.29 | -0.65 | -0.40 | -0.43 | -0.17 | -1.35 | -1.78 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 53.81M | 3.18M | 5.39M | 4.12M | 11.61M | 19.88M | 6.47M | 5.43M | 10.73M | 14.60M |
| Net Income | (45.51M) | (38.75M) | 15.88M | (38.85M) | (39.88M) | (37.67M) | (29.17M) | (25.55M) | (37.91M) | (30.76M) | (22.26M) | (20.71M) |
| EPS | -0.32 | -0.30 | 0.14 | -0.35 | -0.36 | -0.34 | -0.27 | -0.24 | -0.35 | -0.32 | -0.23 | -0.23 |
| Free Cash Flow | (44.36M) | (29.94M) | (31.10M) | (37.14M) | (41.75M) | (36.77M) | (33.51M) | (23.93M) | (38.05M) | (27.69M) | (31.15M) | (25.14M) |
| FCF / Share | -0.31 | -0.26 | -0.28 | -0.34 | -0.38 | -0.34 | -0.31 | -0.22 | -0.35 | -0.29 | -0.32 | -0.28 |
| Operating CF | (44.36M) | (29.72M) | (30.95M) | (36.52M) | (41.70M) | (36.65M) | (33.39M) | (23.61M) | (37.86M) | (27.47M) | (31.14M) | (24.47M) |
| Total Assets | 435.79M | 398.69M | 210.14M | 237.89M | 274.31M | 316.49M | 352.42M | 381.45M | 406.22M | 402.57M | 428.19M | 379.33M |
| Total Debt | 32.79M | 33.57M | 34.76M | 35.01M | 36.95M | 36.49M | 37.63M | 37.84M | 38.23M | 38.92M | 39.51M | 39.89M |
| Cash & Equiv | 157.83M | 112.28M | 58.34M | 39.27M | 58.43M | 69.53M | 53.15M | 51.57M | 61.16M | 66.39M | 58.53M | 66.05M |
| Book Value | 391.51M | 346.18M | 160.03M | 134.95M | 166.76M | 199.52M | 229.17M | 247.67M | 264.45M | 253.11M | 276.60M | 212.94M |
| Return on Equity | -0.12 | -0.11 | 0.10 | -0.29 | -0.24 | -0.19 | -0.13 | -0.10 | -0.14 | -0.12 | -0.08 | -0.10 |
